FDOPA / DOPACIS™ is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum: • In patients with clinically uncertain Parkinsonian Syndromes, in order to help differentiate Essential Tremor from Parkinsonian Syndromes related to idiopathic Parkinson’s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy. DOPACIS™ is unable to discriminate between Parkinson’s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy. • To help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. DOPACIS™ is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia
